

Annexure I
Disclosures to be provided along with the application for listing

1. Details pertaining to the issuer:

1.1 Details of the issuer:

(a) Name, Address, CIN and PAN

Name	Astec LifeSciences Limited
Address	Godrej One, 3 rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai – 400079, Maharashtra, India
CIN	L99999MH1994PLC076236
PAN	AAACA4832D

(b) Line of business: Agrochemicals

(c) Chief Executive (Managing Director/President/CEO/CFO):

Whole Time Director & CEO : Mr. Anurag Roy
CFO : Mr. Madhur Gundecha

(d) Group Affiliation (if any): The Company is a part of the 'Godrej Group'.

1.2 Details of Directors:

Sl. No.	Name, Designation and DIN	Age	Address	Director since	List of other Directorships*
1.	Mr. Nadir B. Godrej Chairman & Director DIN: 00066195	71	The Trees, 40 D, B.G. Kher Marg, 2 nd Floor, Malabar Hill, Mumbai, 400006, Maharashtra	12/10/2015	1. Godrej Agrovet Limited 2. Godrej Industries Limited 3. Godrej Consumer Products Limited 4. Godrej Properties Limited 5. Godrej Tyson Foods Limited 6. Creamline Dairy Products Limited 7. Godrej And Boyce Manufacturing Company Limited 8. Isprava Vesta Private Limited 9. Isprava Hospitality Private Limited 10. Association for Future Agriculture Leaders of India
2.	Mr. Burjis Godrej Director DIN: 08183082	29	40 D, Kher Marg, 2 nd Floor, Malabar Hill, Mumbai, 400006, Maharashtra	25/07/2022	1. Godrej Maxximilk Private Limited 2. Godrej Agrovet Limited

3.	Mr. Ashok V. Hiremath Director DIN: 00349345	66	3, Jal Kiran, 35, Cuffe Parade, Near President Hotel, Coloba, Mumbai-400005, Maharashtra	25/01/1994	1. Dai-Ichi Karkaria Limited 2. Behram Chemicals Private Limited 3. Opus Chemicals Private Limited 4. Astec Crop Care Private Limited 5. Sahbhagi Financial Advisory Private Limited 6. Altimax Financial Services Private Limited
4.	Mr. Balram Singh Yadav Director DIN: 00294803	58	A 3703, Vivarea, Sane Guruji Marg, Mahalaxmi, Near Jacob Circle, Mumbai-400011, Maharashtra	12/10/2015	1. Godrej Agrovvet Limited 2. Sealac Agro Ventures Limited 3. Godrej Tyson Foods Limited 4. Creamline Dairy Products Limited 5. Behram Chemicals Private Limited 6. Poultry and Frozen Food Processors' Association of India
5.	Mr. Anurag Roy Whole Time Director & Chief Executive Officer DIN: 07444595	47	Plot No. 22, Whisper Valley, Near Hussain Shahwali Dargah, Film Nagar, Serlingampally, Golconda, Hyderabad - 500008, Telangana	28/07/2021	1. Behram Chemicals Private Limited
6.	Mr. Rishinaradamangalam Ramakrishna Govindan Independent Director DIN: 02148801	67	904 Marathon Galaxy II, L.B.S. Road, Mulund - West, Mumbai – 400 080, Maharashtra, India	30/01/2020	NA
7.	Dr. Brahma Nand Vyas Independent Director DIN: 02796071	72	45, N Road, Roop Sagar Road, New Keshav Nagar, Girwa, Udaipur- 313001, Rajasthan	29/01/2016	1. World Neem Organisation
8.	Mr. Vijay Kashinath Khot Independent Director DIN: 03520249	72	A2/103, Lok Yamuna, Military Road, Ganeshpada, Marol, Andheri (East), Mumbai-	29/01/2016	NA

			400059, Maharashtra		
9.	Mr. Nandkumar Dhekne Independent Director DIN: 02189370	64	1238 A, Svanand, 32nd G cross, 26th Main Jayanagar, 4th T Block, Bangalore – 560041, Karnataka	18/12/2020	1. John Cockerill India Limited 2. Elantas Beck India Limited
10.	Ms. Anjali Rajesh Gupte Independent Director DIN: 00104884	51	82-B, Miramar, 3 Nepeansea Road, Near St. Stephen Church, Kemps Corner, Mumbai – 400026, Maharashtra	18/12/2020	1. Havas Media India Private Limited 2. Arena India Private Limited 3. Socialyse India Private Limited 4. Havas Worldwide India Private Limited 5. Think Design Collaborative Private Limited 6. Shobiz Experiential Communications Private Limited

*Excludes Foreign Companies

1.3 Details of change in directors in last three financial years including change, if any, in the current year:

Sl. No.	Name, designation and DIN	Date of appointment/ resignation	Date of cessation (in case of resignation)	Remarks/ reasons for change
1	Mr. Sitendu Sharma Independent Director DIN: 01956423	27/09/2007	30/01/2020	Resignation from Directorship
2	Mr. Rishinaradamangalam Ramakrishna Govindan Independent Director DIN: 02148801	30/01/2020	-	Appointment as an Independent Director
3	Mr. Vinod C. Malshe Independent Director DIN: 00642540	21/09/2020		Cessation due to completion of tenure
4	Dr. Leena Raje Independent Director DIN: 06961551	21/09/2020		Cessation due to completion of tenure
5	Mr. Nandkumar Dhekne Independent Director DIN: 02189370	18/12/2020	-	Appointment as an Independent Director

6	Ms. Anjali Rajesh Gupte Independent Director DIN: 00104884	18/12/2020	-	Appointment as an Independent Director
7	Mr. Arijit Mukherjee Whole Time Director DIN: 07334111	28/07/2021	-	Resignation as a Whole Time Director
8	Mr. Anurag Roy Whole Time Director & Chief Executive Officer DIN: 07444595	28/07/2021	-	Appointment as a Whole Time Director & Chief Executive Officer
9.	Mr. Ashok V. Hiremath Director DIN: 00349345	01/04/2022	-	Change in designation from Managing Director to Non-Executive Director
10.	Mr. Rakesh Dogra Director DIN: 07334098	-	02/05/2022	Resignation from Directorship
11.	Mr. Burjis Godrej Director DIN: 08183082	25/07/2022	-	Appointment as an Additional, Non-Executive, Non-Independent Director
12.	Mr. Burjis Godrej Director DIN: 08183082	25/07/2022	-	Appointment as Non-Executive, Non-Independent Director (Pursuant to Postal Ballot results declared on 19/09/2022)

**1.4 List of top 10 holders of equity shares of the Company as on 31st December, 2022
(As per PAN):**

Sl. No.	Name and category of shareholder	Total no. of Equity Shares	No of shares in demat form	Total shareholding as % of total no. of equity shares
1	GODREJ AGROVET LIMITED	12,699,054	12,699,054	64.77
2	NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND	468,589	468,589	2.39
3	KAUSHIK DAGA	395,000	395,000	2.01
4	ASHOK VISHWANATH HIREMATH	390,802	390,802	1.99
5	ICICI PRUDENTIAL MULTICAP FUND	390,776	390,776	1.99
6	SHREANS DAGA	381,081	381,081	1.94
7	GOVERNMENT PENSION FUND GLOBAL	280,000	280,000	1.43
8	NIPPON LIFE INDIA TRUSTEE	257,718	257,718	1.31

Sl. No.	Name and category of shareholder	Total no. of Equity Shares	No of shares in demat form	Total shareholding as % of total no. of equity shares
	LTD-A/C NIPPON INDIA MULTI CAP FUND			
9	ICICI PRUDENTIAL SMALLCAP FUND	223,351	223,351	1.14
10	Own Infracon Private Limited	189,510	189,510	0.97
	TOTAL	1,56,75,881	1,56,75,881	79.96

1.5 Details of Statutory Auditor

Name and address	Date of appointment	Remarks
M/s. B S R & Co. LLP, Chartered Accountants Address: 14 th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063	25/07/2022	Appointed for a term of five years commencing from FY 2022-23 to 2026-27.

1.6 Details of the change in statutory auditors in last three financial years including any change in the current year:

Sl. No.	Name, address	Date of appointment/ resignation	Date of cessation (in case of resignation)	Remarks (viz. reasons for change etc)
1.	M/s. B S R & Co. LLP, Chartered Accountants Address: 14 th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063	25/07/2022	-	Appointed for a second term of five years commencing from FY 2022-23 to FY 2026-27
2.	M/s. B S R & Co. LLP, Chartered Accountants Address: 5 th Floor, Lodha Excelus, Apollo Mills Compound, N. M. Joshi Marg, Mahalaxmi, Mumbai – 400 011, Maharashtra, India	28/07/2017	-	Appointed for a term of five years commencing from FY 2017-18 to 2021-22

Sl. No.	Name, address	Date of appointment/ resignation	Date of cessation (in case of resignation)	Remarks (viz. reasons for change etc)
3.	M/s. Shah & Kathariya, Chartered Accountants Room No 6, 4th Floor, Kermani Bldg, Address: 27, Sir P. M. Road, Opp. Citi Bank, Fort, Mumbai - 400001, Maharashtra, India	28/07/2017	-	Ceased to be the Statutory Auditors upon completion of term

1.7 List of top 10 NCD holders: Not Applicable

1.8 List of top 10 CP holders (as on 17th February, 2023): Annexure (i)

2. Material Information:

2.1. Details of all default(s) and/ or delay in payments of interest and principal of CPs, (including technical delay), debt securities, term loans, external commercial borrowings and other financial indebtedness including corporate guarantee issued in the past 5 financial years including in the current financial year.	Nil
2.2. Ongoing and/or outstanding material litigation and regulatory strictures, if any.	None
2.3. Any material event/ development having implications on the financials/ credit quality including any material regulatory proceedings against the issuer/ promoters, tax litigations resulting in material liabilities, corporate restructuring event which may affect the issue or the investor's decision to invest/ continue to invest in the CP.	None

3. Details of borrowings of the company:

3.1. Details of debt securities and CPs as on 31 st December, 2022.	<u>Annexure (ii)</u>
3.2 Details of secured/ unsecured loan facilities/ bank fund based facilities/ rest of the borrowing (if any, including hybrid debt like foreign currency convertible bonds (FCCB), optionally convertible debentures/ preference shares) from banks or financial institutions or financial creditor, as on last quarter ended 31st December, 2022.	Enclosed as <u>Annexure (iii)</u>
3.3 The amount of corporate guarantee or letter of comfort issued by the issuer	Nil

along with name of the counterparty (like name of the subsidiary, JV entity, group company, etc.) on behalf of whom it has been issued, contingent liability including DSRAs guarantees/ any put option etc.:	
---	--

4. Issue Information:

4.1. Details of current tranche including ISIN, amount, date of issue, maturity, all credit ratings including unaccepted ratings, date of rating, name of credit rating agency, its validity period, declaration that the rating is valid as at the date of issuance and listing, details of issuing and paying agent and other conditions, if any.	Enclosed as <u>Annexure (iv)</u>
4.2. CP borrowing limit, supporting board resolution for CP borrowing, details of CP issued during the last 15 months.	The Board of Directors have approved CP borrowing limit of Rs.300 Crore. The certified copy of the resolution is enclosed herewith as <u>Annexure (v)</u> . Further, the details of CPs issued during last 15 months are enclosed as <u>Annexure (vi)</u> .
4.3. End-use of funds.	General corporate purposes
4.4. Credit Support/enhancement (if any): a) Details of instrument, amount, guarantor company; b) Copy of the executed guarantee; c) Net worth of the guarantor company; d) Names of companies to which guarantor has issued similar guarantee; e) Extent of the guarantee offered by the guarantor company; and f) Conditions under which the guarantee will be invoked.	None
4.5. Where an issue is made by an issuer who has been in existence for less than three years, a disclosure that the issue is open for subscription only to Qualified Institutional Buyers.	N.A.

5. Financial Information:

5.1. a. Audited/ limited review half yearly consolidated (wherever available) and standalone financial information (Profit & Loss statement, Balance Sheet and Cash Flow statement) along with auditor qualifications, if any, for last three years along with latest available financial results, if the issuer has been	The Annual Reports of the Company for the last three Financial Years (FY 2019-20, FY 2020-21 and FY 2021-22) are available at the following weblink of the Company:
---	---

<p>in existence for a period of three years and above; or,</p> <p>b. Audited/ limited review half yearly consolidated (wherever available) and standalone financial information (Profit & Loss statement, Balance Sheet and Cash Flow statement) along with auditor qualifications, if any, pertaining to the years of existence, if the issuer has been in existence for less than three years.</p>	<p><u>FY 2019-20:</u> http://www.astecsls.com/annual-reports.aspx</p> <p><u>FY 2020-21:</u> http://www.astecsls.com/annual-reports.aspx</p> <p><u>FY 2021-22:</u> http://www.astecsls.com/annual-reports.aspx</p> <p>Further, the Unaudited Financial Results alongwith Limited Review Report of the Statutory Auditors for the Quarter and Nine Months' period ended 31st December, 2022 are enclosed as <u>Annexure (vii)</u></p>
<p>5.2. Latest audited financials should not be older than six months from the date of application for listing.</p> <p>5.3. Provided that listed issuers (who have already listed their specified securities and/ or NCDs and/ or NCRPS) who are in compliance with SEBI LODR Regulations, 2015, and/ or issuers (who have outstanding listed CPs) who are in compliance with the continuous listing conditions, may file unaudited financials with limited review for the stub period in the current year, subject to making necessary disclosures in this regard including risk factors</p>	<p>The Unaudited Financial Results alongwith Limited Review Report of the Statutory Auditors for the Quarter and Nine Months' period ended 31st December, 2022 are enclosed as <u>Annexure (vii)</u></p>
<p>5.4. Latest available limited review quarterly financial results in case an issuer is not having any listed specified securities and is required to prepare such results on quarterly basis for consolidation of financial results of its holding company, under the requirement of any applicable law(s).</p>	<p>Not Applicable</p>

6. Asset Liability Management (ALM) Disclosures: Not Applicable

6.1. NBFCs/ HFCs seeking to list their CPs shall also make disclosures as specified in Chapter III of this circular.

6.2. On approval of the listing application by the concerned stock exchange(s), the disclosures so provided along with the application for listing, shall be made available on the website of the concerned stock exchange(s).

Declaration

We, Astec LifeSciences Limited ("the Company"), hereby confirm that this Disclosure Document for listing of Commercial Papers (INE563J14AE5) contains all the disclosures as prescribed under the Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 and SEBI Updated Operational Circular for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 1st December, 2022, as amended from time to time.

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer

Date: 17th February, 2023

Place: Mumbai

Annexure (i)**List of Top 10 CP Holders as on 17th Feb 2023**

S.No	Name of Holder	Category	Face value	CP holding percentage as a percentage of total CP outstanding of the issuer
1	ICICI BANK	MF	500000	37.50%
2	Aditya Birla Sun Life Mutual Fund	MF	500000	25.00%
3	RBL BANK	MF	500000	25.00%
4	UTI Mutual Fund	MF	500000	12.50%

Annexure (ii)

[illegible]

Annexure (iii)

Details of secured/ unsecured loan facilities/ bank fund based facilities/ rest of the borrowing, if any, including hybrid debt like foreign currency convertible bonds (FCCB), optionally convertible debentures / preference shares from banks or financial institutions or financial creditors, as on last quarter end in the following format:

Sr. No	Lender's name/ Name of the Bank	Nature of facility/ instrument	Amount sanctioned (In Crores)	Principal Amount outstanding (In Crore)	Repayment date / schedule	Security, if applicable	Credit rating, if applicable	Asset classification
1	AXIS BANK	Buyers Credit	159.00					
		BC		0.38	29-Mar-23	Not Applicable	Not Applicable	Standard
		BC		0.38	29-Mar-23	Not Applicable	Not Applicable	Standard
		BC		2.99	13-Jan-23	Not Applicable	Not Applicable	Standard
		BC		1.42	17-May-23	Not Applicable	Not Applicable	Standard
		BC		0.82	25-Apr-23	Not Applicable	Not Applicable	Standard
		BC		0.82	25-Apr-23	Not Applicable	Not Applicable	Standard
		BC		0.39	25-Apr-23	Not Applicable	Not Applicable	Standard
		BC		0.45	25-Apr-23	Not Applicable	Not Applicable	Standard
		BC		0.23	25-Apr-23	Not Applicable	Not Applicable	Standard
		BC		1.13	28-Apr-23	Not Applicable	Not Applicable	Standard
		BC		2.20	28-Apr-23	Not Applicable	Not Applicable	Standard
		BC		0.41	10-May-23	Not Applicable	Not Applicable	Standard
		BC		4.09	24-May-23	Not Applicable	Not Applicable	Standard
		BC		1.74	26-May-23	Not Applicable	Not Applicable	Standard
		BC		4.59	28-Feb-23	Not Applicable	Not Applicable	Standard
		BC - Exchange rate diff		0.80				
		TOTAL		22.83				
2	HDFC Bank	Buyer Credit	97.00					
		BC		3.90	19-Jan-23	Not Applicable	Not Applicable	Standard
		BC		3.84	25-Jan-23	Not Applicable	Not Applicable	Standard
		BC		0.42	26-Apr-23	Not Applicable	Not Applicable	Standard
		BC - Exchange rate diff		0.38				
		TOTAL		8.53				
3	RBL BANK	Long Term Debt / WCDL	50.00	3.70	17-Oct-23	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		3.10	17-Oct-23	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		2.00	27-Oct-23	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		2.00	28-Dec-23	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		3.18	14-Jan-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		5.41	25-Jan-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		2.55	10-Feb-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		4.53	06-Mar-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		4.54	21-Mar-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		3.12	10-Apr-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		3.00	16-May-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		2.01	22-May-24	Not Applicable	Not Applicable	Standard
		Long Term Debt / WCDL		3.60	11-Jun-24	Not Applicable	Not Applicable	Standard
		TOTAL		42.74				

Annexure (iii)

Details of secured/ unsecured loan facilities/ bank fund based facilities/ rest of the borrowing, if any, including hybrid debt like foreign currency convertible bonds (FCCB), optionally convertible debentures / preference shares from banks or financial institutions or financial creditors, as on last quarter end in the following format:

4	ICICI BANK	Short Term Debt / WCDL / CC	50.00					
		EPC		8.00	18-Jan-23	Not Applicable	Not Applicable	Standard
		EPC		10.00	22-Mar-23	Not Applicable	Not Applicable	Standard
		EPC		15.00	23-Mar-23	Not Applicable	Not Applicable	Standard
		CC		12.59	01-Jan-23	Not Applicable	Not Applicable	Standard
		TOTAL		45.59				
5	MIZUHO BANK	Short Term Debt / WCDL	50.00					
				25.00	17-Jan-23	Not Applicable	Not Applicable	Standard
				25.00	13-Mar-23	Not Applicable	Not Applicable	Standard
		TOTAL		50.00				

Annexure (iv)

Details of current tranche including ISIN, amount, date of issue, maturity, all credit ratings including unaccepted ratings, date of rating, name of credit rating agency, its validity period, declaration that the rating is valid as at the date of issuance and listing, details of issuing and paying agent and other conditions, if any:

Deal Details

Issue Reference : ASTEC-CP-107
ISIN CODE : INE563J14AE5
CP (Maturity Value) Rs. : 250,000,000
Date of Issue : 17/02/2023
Maturity Date : 17/05/2023

Credit Rating No.

Issued by : ICRA
Credit Rating : A1 +
Date of Rating : 30/01/2023
Validity of issuance : Three Months
Validity : 15/09/2023
For Amount : 30,000 Lakhs

Cp Borrowing Limit : 30,000 Lakhs
Issuing & Payment Agent : ICICI Bank Ltd.
Branch : Vashi, Navi Mumbai.

Declaration

We, Astec LifeSciences Limited ("the Company"), hereby confirm that the details of credit rating as mentioned above are valid as on date and the date of listing.

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)
Date: 17th February, 2023
Place: Mumbai

Issue of Commercial Papers intended to be listed



Astec Life Sciences Ltd.

ANNEXURE (V)

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF ASTEC LIFESCIENCES LIMITED HELD ON MONDAY, 30TH JANUARY, 2023 AT 3.30 P.M.

“RESOLVED THAT in supersession of the resolution passed by the Board of Directors at its Meeting held on 25th January, 2022, the approval of the Board of Directors be and is hereby granted for raising funds by way of issuance of Commercial Paper(s) (“CPs”) upto a limit of Rs.300 Crore (Rupees Three Hundred Crore Only), for a maturity period of 7 (seven) days or more but not exceeding 6 (six) months from the date of issue, in terms of the applicable provisions of the Reserve Bank Commercial Paper Directions, 2012 and the Companies Act, 2013 [including any amendment(s) /modification(s) / re-enactment(s) thereto], subject to credit rating from ICRA Limited and the permission of the Reserve Bank of India (RBI), if applicable and such other approval(s) as may be necessary.”

“RESOLVED FURTHER THAT the approval of the Board of Directors be and is hereby granted for authorizing the following Director(s) / Official(s) / Authorised Signatory(ies) of the Company (“Authorized Signatories”), viz.:

1. Mr. Anurag Roy, Whole-Time Director & Chief Executive Officer;
2. Mr. Arijit Mukherjee, Chief Operating Officer;
3. Mr. Madhur Gundecha, Chief Financial Officer;
4. Ms. Tejashree Pradhan, Company Secretary & Compliance Officer;
5. Mr. S. Varadaraj, Authorised Signatory;
6. Mr. Vivek Raizada, Authorised Signatory;
7. Mr. Amit Pendse, Authorised Signatory;
8. Mr. Mathan Ramasamy, Authorised Signatory;

be and are hereby severally authorized to sign and execute for and on behalf of the Company, CPs within the aforesaid limits, all such agreement(s) and/or document(s) as may be necessary in connection with the issuance of CPs and to do all such acts, deeds and things as may be necessary for or incidental to the aforesaid purpose including, inter alia, determining the discount rate and the appointment and remuneration of Merchant Bankers, Dealers and Issuing and Paying Agents.”

“RESOLVED FURTHER THAT the Common Seal of the Company be affixed on the CPs (to be issued by the Company from time to time subject to the aforesaid limits), agreement(s) and/or other document(s) if required, in the presence of / under the signatures of any 2 (two) of the Authorized Signatories.”

“RESOLVED FURTHER THAT the Authorized Signatories be and are hereby severally authorized to appoint the Registrar and Share Transfer Agent for the issue of CPs by the Company and to do all such act(s), deed(s), matter(s) and thing(s), as may be necessary to give effect to this resolution.”



Regd. Office :
"Godrej One", 3rd Floor,
Proshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No. : 022- 25188010
Fax No. : 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecsl.com
CIN : L99999MH1994PLC076236



Astec LifeSciences Ltd.

"RESOLVED FURTHER THAT a copy of the foregoing resolution certified to be true by any Director of the Company or the Company Secretary or the Chief Financial Officer be furnished to the concerned authority(ies) / person(s) and they be requested to act thereon."

For Astec LifeSciences Limited

**Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)**

Date and Place of signing: 17th February, 2023, Mumbai



Regd. Office :
"Godrej One", 3rd Floor,
Prakashnagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No. : 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecsls.com
CIN : L99999MH1994PLC076236

Annexure (vi)

Details of Commercial paper Raised in the last 15 months

Sr	Series	Date of Issuance	Date of Maturity	Amount Issued in Rs Cr	Amount Outstanding in Rs Cr	IPA	CRA	Rating	Rated Amount	Credit Rating Agency
1	ASTEC-CP-54	17-Aug-21	18-Oct-21	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
2	ASTEC-CP-55	23-Aug-21	01-Nov-21	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
3	ASTEC-CP-56	22-Sep-21	21-Dec-21	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
4	ASTEC-CP-57	04-Oct-21	20-Dec-21	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
5	ASTEC-CP-58	14-Oct-21	12-Jan-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
6	ASTEC-CP-59	18-Oct-21	17-Jan-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
7	ASTEC-CP-60	25-Oct-21	28-Dec-21	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
8	ASTEC-CP-61	01-Nov-21	28-Jan-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
9	ASTEC-CP-62	18-Nov-21	16-Feb-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
10	ASTEC-CP-63	14-Dec-21	14-Feb-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
11	ASTEC-CP-64	23-Dec-21	24-Mar-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
12	ASTEC-CP-65	27-Dec-21	28-Mar-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
13	ASTEC-CP-66	28-Dec-21	22-Feb-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
14	ASTEC-CP-67	12-Jan-22	12-Apr-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
15	ASTEC-CP-68	17-Jan-22	13-Apr-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
16	ASTEC-CP-69	28-Jan-22	28-Apr-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
17	ASTEC-CP-70	14-Feb-22	13-May-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
18	ASTEC-CP-71	16-Feb-22	15-Jul-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
19	ASTEC-CP-72	22-Feb-22	24-May-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
20	ASTEC-CP-73	24-Mar-22	23-May-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
21	ASTEC-CP-74	28-Mar-22	27-Jun-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
22	ASTEC-CP-75	12-Apr-22	11-Jul-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
23	ASTEC-CP-76	13-Apr-22	07-Jul-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
24	ASTEC-CP-77	13-Apr-22	10-Oct-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
25	ASTEC-CP-78	13-Apr-22	06-Oct-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
26	ASTEC-CP-79	27-Apr-22	23-Jun-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
27	ASTEC-CP-80	28-Apr-22	14-Jul-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
28	ASTEC-CP-81	29-Apr-22	08-Jul-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
29	ASTEC-CP-82	23-May-22	19-Aug-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
30	ASTEC-CP-83	23-Jun-22	02-Sep-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
31	ASTEC-CP-84	27-Jun-22	17-Aug-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
32	ASTEC-CP-85	29-Jun-22	26-Aug-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
33	ASTEC-CP-86	30-Jun-22	29-Aug-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
34	ASTEC-CP-87	08-Jul-22	28-Sep-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
35	ASTEC-CP-88	11-Jul-22	26-Sep-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
36	ASTEC-CP-89	17-Aug-22	15-Nov-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
37	ASTEC-CP-90	19-Aug-22	17-Nov-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
38	ASTEC-CP-91	23-Aug-22	21-Nov-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
39	ASTEC-CP-92	26-Aug-22	25-Nov-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
40	ASTEC-CP-93	29-Aug-22	24-Nov-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
41	ASTEC-CP-94	02-Sep-22	30-Nov-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
42	ASTEC-CP-95	26-Sep-22	23-Dec-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
43	ASTEC-CP-96	28-Sep-22	26-Dec-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
44	ASTEC-CP-97	15-Nov-22	13-Feb-23	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
45	ASTEC-CP-98	17-Nov-22	14-Feb-22	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
46	ASTEC-CP-99	24-Nov-22	22-Feb-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
47	ASTEC-CP-100	25-Nov-22	23-Feb-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
48	ASTEC-CP-101	12-Dec-22	10-Mar-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
49	ASTEC-CP-102	26-Dec-22	24-Mar-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
50	ASTEC-CP-103	30-Dec-22	29-Mar-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
51	ASTEC-CP-104	17-Jan-23	17-Feb-23	25.00		ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
52	ASTEC-CP-105	01-Feb-23	28-Apr-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
53	ASTEC-CP-106	14-Feb-23	12-May-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
54	ASTEC-CP-107	17-Feb-23	17-May-23	25.00	25.00	ICICI BANK LTD	ICRA	A1+	Rs. 300 Cr	ICRA Limited
Total				1,350.00	200.00					



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31st December, 2022



(Rs. in Lakh)

Sr. No	Particulars	STANDALONE					
		Quarter Ended			Nine months Ended		Year Ended
		31-Dec-22 (Unaudited)	30-Sep-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Mar-22 (Audited)
I	Revenue from Operations	11,718.09	19,974.70	17,335.32	50,119.42	40,458.41	67,656.61
II	Other Income	378.12	398.21	195.98	1,047.00	366.30	1,046.34
III	Total Income (I+II)	12,096.21	20,372.91	17,531.30	51,166.42	40,824.71	68,702.95
IV	Expenses						
	Cost of materials consumed	11,102.36	13,468.35	11,281.99	38,434.36	29,079.60	44,481.50
	Changes in inventories of finished goods and work-in-progress	(4,130.33)	(1,188.70)	(2,006.21)	(6,934.54)	(6,832.21)	(5,800.42)
	Employee benefits expense	1,139.68	1,502.74	1,285.34	3,940.20	3,359.12	5,031.41
	Finance costs	588.38	452.10	256.36	1,433.51	576.02	909.02
	Depreciation and amortisation expense	881.08	818.41	907.18	2,593.72	2,376.04	3,441.59
	Other expenses	2,393.63	2,864.15	2,487.91	7,593.21	5,989.88	8,535.77
	Total expenses (IV)	11,974.80	17,917.05	14,212.57	47,060.46	34,548.45	56,598.87
V	Profit / (loss) before exceptional items and tax (III - IV)	121.41	2,455.86	3,318.73	4,105.96	6,276.26	12,104.08
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	121.41	2,455.86	3,318.73	4,105.96	6,276.26	12,104.08
VIII	Tax Expense:						
	(1) Current tax	(158.83)	162.59	798.10	102.39	1,506.65	2,861.27
	(2) Deferred tax	197.45	463.47	46.89	952.00	92.07	261.01
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	82.79	1,829.80	2,473.74	3,051.57	4,677.54	8,981.80
X	Profit / (loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	82.79	1,829.80	2,473.74	3,051.57	4,677.54	8,981.80
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(0.50)	(5.89)	(1.50)	(17.66)	(0.72)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.13	0.12	1.48	0.38	4.44	0.18
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	82.42	1,829.42	2,469.33	3,050.45	4,664.32	8,981.26
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.57	1,960.46	1,959.11	1,960.57	1,959.11	1,959.76
XVII	Other Equity excluding Revaluation Reserve						37,638.34
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	0.42	9.33	12.63	15.57	23.88	45.85
	(2) Diluted (in Rs.)	0.42	9.33	12.62	15.56	23.86	45.83

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Monday, 30th January, 2023
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review opinion.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- The figures for the previous year/periods have been re-grouped/re-classified wherever necessary, to conform to current period's presentation.

For Astec LifeSciences Limited

ANURAG ROY
Digitally signed by ANURAG ROY
DN: cn=ANURAG ROY, o=ASTEC LIFE SCIENCES LIMITED, email=anurag.roy@astecsl.com, c=IN

Anurag Roy

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : January 30, 2023

BURJIS TEHMURASP PARDIWALA
Digitally signed by BURJIS TEHMURASP PARDIWALA
DN: cn=BURJIS TEHMURASP PARDIWALA, email=burjis.tehmurasp.pardiwala@astecsl.com, c=IN

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.01.30
16:27:11 +05'30'



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsls.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	STANDALONE					
		Quarter Ended			Nine months Ended		Year Ended
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	1.04	1.13	0.94	1.04	0.94	1.05
II	Net Worth (in Rs. Lakh)	42,394.08	42,303.73	35,255.02	42,394.08	35,255.02	39,598.10
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-	-
IV	Net profit after tax (in Rs. Lakh)	82.78	1,829.80	2,473.74	3,051.56	4,677.54	8,981.80
V	Basic Earnings per share (in Rs.)	0.42	9.33	12.63	15.57	23.88	45.85
VI	Diluted Earnings per share (in Rs.)	0.42	9.33	12.62	15.56	23.86	45.83
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	0.87	0.76	0.81	0.87	0.81	0.71
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	2.50	6.35	12.72	1.27	11.56	13.10
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	2.63	6.75	14.19	4.90	13.25	14.67
XI	Long term debt to working capital (refer note 1)	0.84	0.49	3.00	0.84	3.00	0.62
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	0.00
XIII	Current liability ratio (refer note 1)	0.95	0.91	0.98	0.95	0.98	0.98
XIV	Total debts to total assets (refer note 1)	0.37	0.34	0.35	0.37	0.35	0.31
XV	Debtors turnover (refer note 1)	2.35	2.88	4.63	2.88	3.00	2.92
XVI	Inventory turnover (refer note 1)	2.00	4.00	3.60	2.96	3.34	4.62
XVII	Operating EBITDA margin (%)	10.3%	16.7%	24.7%	14.1%	21.9%	22.8%
XVIII	Net profit margin (%)	0.7%	9.2%	14.3%	6.1%	11.6%	13.3%

1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA. The rating "[ICRA] A1+" and "[ICRA] AA-" has been assigned for its short term facilities (including commercial paper) and long term facilities respectively.

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings + Current maturities of long term debts) / Current Assets - (Current liabilities-Current maturities of long term debts)

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : Current liabilities / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Total Sales / Average Inventory (annualised).

ANURAG ROY

Digitally signed by ANURAG ROY
DN: c=IN, o=PERSONAL,
pseudonym=fd462261cb5babaf782f10
a55df4bfa5068c089c137c932d030eb3
532043979b, postalCode=500008,
st=TELANGANA,
serialNumber=efbf19cac1bf08a3c787
1890fac5e2a98428d836504bee31fe45a
c4befc2969e, cn=ANURAG ROY
Date: 2023.01.30 15:57:46 +05'30'

BURJIS TEHMURASP PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.01.30
16:27:34 +05'30'



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2022



(Rs. in Lakh)

Sr. No	Particulars	CONSOLIDATED					
		Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-22 (Unaudited)	30-Sep-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Mar-22 (Audited)
I	Revenue from Operations	11,718.09	19,974.70	17,335.32	50,119.42	40,458.41	67,656.61
II	Other Income	378.88	398.59	195.98	1,048.51	366.30	1,046.78
III	Total Income (I+II)	12,096.97	20,373.29	17,531.30	51,167.93	40,824.71	68,703.39
IV	Expenses						
	Cost of materials consumed	11,102.36	13,468.35	11,281.99	38,434.36	29,079.60	44,481.50
	Changes in inventories of finished goods and work-in-progress	(4,130.33)	(1,188.70)	(2,006.21)	(6,934.54)	(6,832.21)	(5,800.42)
	Employee benefits expense	1,139.68	1,502.74	1,285.34	3,940.20	3,359.12	5,031.41
	Finance costs	587.74	451.45	255.55	1,431.58	573.58	905.77
	Depreciation and amortisation expense	879.59	816.92	905.69	2,589.25	2,371.57	3,435.63
	Other expenses.	2,393.91	2,864.43	2,488.21	7,594.03	5,990.77	8,536.92
	Total expenses (IV)	11,972.95	17,915.19	14,210.57	47,054.88	34,542.43	56,590.81
V	Profit / (loss) before exceptional items and tax (III - IV)	124.02	2,458.10	3,320.73	4,113.05	6,282.28	12,112.58
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	124.02	2,458.10	3,320.73	4,113.05	6,282.28	12,112.58
VIII	Tax Expense:						
	(1) Current tax	(158.12)	163.20	798.60	104.32	1,508.16	2,863.40
	(2) Deferred tax	197.41	463.42	46.88	951.86	92.01	260.92
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	84.73	1,831.48	2,475.25	3,056.87	4,682.11	8,988.26
X	Profit / (loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	84.73	1,831.48	2,475.25	3,056.87	4,682.11	8,988.26
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(0.50)	(5.89)	(1.50)	(17.66)	(0.72)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.13	0.12	1.48	0.38	4.44	0.18
	B (i) Items that will be reclassified to profit or loss	0.27	0.42	0.47	1.15	0.61	(0.18)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	84.63	1,831.52	2,471.31	3,056.91	4,669.50	8,987.54
XVI	Net Profit/(loss) attributable to:						
	- Owners	83.97	1,830.82	2,474.68	3,054.78	4,680.40	8,985.86
	- Non controlling interests	0.76	0.66	0.57	2.09	1.71	2.40
	Total Comprehensive Income attributable to:	-	-	-	-	-	-
	- Owners	83.88	1,830.86	2,470.74	3,054.82	4,667.79	8,985.14
	- Non controlling interests	0.76	0.66	0.57	2.09	1.71	2.40
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.57	1,960.46	1,959.11	1,960.57	1,959.11	1,959.76
XVIII	Other Equity excluding Revaluation Reserve						37,689.78
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	0.43	9.34	12.63	15.58	23.89	45.87
	(2) Diluted (in Rs.)	0.43	9.34	12.62	15.58	23.88	45.85

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Monday, 30th January, 2023
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review opinion.
- The Group has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- The figures for the previous year/periods have been re-grouped/re-classified wherever necessary, to conform to current period's presentation.

For Astec LifeSciences Limited

ANURAG ROY
Digitally signed by ANURAG ROY
DN: cn=ANURAG ROY,
o=ASTEC LIFE SCIENCES LIMITED,
ou=ASTEC LIFE SCIENCES LIMITED,
email=anurag.roy@astecsl.com,
c=IN

Anurag Roy

BURJIS TEHMURASP PARDIWALA
Digitally signed by BURJIS TEHMURASP PARDIWALA
Date: 2023.01.30
16:27:51 +05'30'

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : January 30 , 2023



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra
Website: www.astecsls.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	CONSOLIDATED					
		Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	1.04	1.13	0.94	1.04	0.94	1.05
II	Net Worth (in Rs. Lakh)	42,449.88	42,358.07	35,306.05	42,449.88	35,306.05	39,649.54
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-	-
IV	Net profit after tax (in Rs. Lakh)	84.73	1,831.48	2,475.25	3,056.87	4,682.11	8,988.26
V	Basic Earnings per share (in Rs.)	0.43	9.34	12.63	15.58	23.89	45.87
VI	Diluted Earnings per share (in Rs.)	0.43	9.34	12.62	15.58	23.88	45.85
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	0.87	0.76	0.81	0.87	0.81	0.70
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	2.52	6.39	12.95	1.27	11.74	13.23
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	2.63	6.76	14.23	4.90	13.30	14.72
XI	Long term debt to working capital (refer note 1)	0.83	0.49	2.83	0.83	2.83	0.61
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	0.00
XIII	Current liability ratio (refer note 1)	0.95	0.91	0.99	0.95	0.99	0.98
XIV	Total debts to total assets (refer note 1)	0.37	0.34	0.35	0.37	0.35	0.31
XV	Debtors turnover (refer note 1)	2.35	2.88	4.63	2.88	3.00	2.92
XVI	Inventory turnover (refer note 1)	2.00	4.00	3.60	2.96	3.34	4.62
XVII	Operating EBITDA margin (%)	10.3%	16.7%	24.7%	14.1%	21.9%	22.8%
XVIII	Net profit margin (%)	0.7%	9.2%	14.3%	6.1%	11.6%	13.3%

1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA. The rating "[ICRA] A1+" and "[ICRA] AA-" has been assigned for its short term facilities (including commercial paper) and long term facilities respectively.

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings + Current maturities of long term debts) / Current Assets - (Current liabilities-Current maturities of long term debts)

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : Current liabilities / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (annualised)

Inventory turnover : Total Sales / Average Inventory (annualised).

ANURAG ROY

Digitally signed by ANURAG ROY
DN: c=IN, o=PERSONAL,
pseudonym=fd462261cb5baba782f1
0a55df4bfa5068c089c137c932d030eb
3532043979b, postalCode=500008,
st=TELANGANA,
serialNumber=eebf19cac1bf08e3c787
1890fac6e2a98428d836504bee31fe45
ac4befc2969e, cn=ANURAG ROY
Date: 2023.01.30 15:59:43 +05'30'

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.01.30
16:28:12 +05'30'

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited standalone financial results of Astec LifeSciences Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 and Regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Astec LifeSciences Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021,

B S R & Co. LLP

Limited Review Report (Continued)

Astec LifeSciences Limited

including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.01.30
16:29:12 +05'30'

Burjis Pardiwala

Partner

Mumbai

30 January 2023

Membership No.: 103595

UDIN:23103595BGTPEA8124

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited consolidated financial results of Astec LifeSciences Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 and Regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Astec LifeSciences Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities mentioned in Annexure I to the Statement:
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

Astec LifeSciences Limited

6. We did not review the interim financial information of one subsidiary included in the Statement, whose interim financial information reflect total revenues of Rs. 3.47 lakhs and Rs. 9.61 lakhs, total net profit after tax of Rs. 2.23 lakhs and Rs. 6.09 lakhs and total comprehensive income of Rs. 2.23 lakhs and Rs. 6.09 lakhs, for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively, as considered in the Statement. This interim financial information have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of one subsidiary which has not been reviewed, whose interim financial information reflect total revenues of Rs. Nil and Rs. Nil, total net profit after tax of Rs. Nil and Rs. Nil and total comprehensive income Rs. Nil and Rs. Nil, for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2023.01.30
16:28:48 +05'30'

Burjis Pardiwala

Partner

Mumbai

30 January 2023

Membership No.: 103595

UDIN:23103595BGTPEB8267

Limited Review Report (Continued)**Astec LifeSciences Limited****Annexure I**

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Subsidiary Company
3	Comercializadora Agricola Agroastrachem Cia Ltda	Subsidiary Company